[ 18 F]FDG-PET/CT imaging in assessing cancer-induced cachexia

Area of Science:

• Oncology
• Nuclear Medicine
• Metabolic Research

Background:

• Cancer-induced cachexia presents significant clinical challenges due to complex causes, late detection, and limited treatments.
• Precision oncology and systemic metabolic assessment are advancing patient management strategies.

Purpose of the Study:

• To explore the utility of [18F]fluorodeoxyglucose positron emission tomography combined with computed tomography ([18F]FDG-PET/CT) in assessing metabolic alterations related to cachexia.
• To evaluate [18F]FDG-PET/CT's potential beyond tumor detection for managing cancer cachexia.

Main Methods:

• Review of current evidence on [18F]FDG-PET/CT for cachexia assessment.
• Exploration of integrating PET-derived data with CT-based body composition analysis.

Main Results:

• Growing evidence indicates [18F]FDG-PET/CT can identify early metabolic dysfunction in tissues affected by cachexia, preceding significant weight loss.
• Metabolic shifts detected by [18F]FDG-PET/CT may serve as early biomarkers for cachexia identification and monitoring.
• Current evidence is primarily based on retrospective or heterogeneous studies.

Conclusions:

• Prospective trials in well-defined patient populations are necessary to validate [18F]FDG-PET/CT for cachexia management.
• Successful validation could broaden the application of PET/CT to metabolic assessment, improving supportive care in oncology.